دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Adjuvant Interferon [alpha]-2b for High-Risk Melanoma.
Schwartz, Gary K. MD 1,2,,
doi : 10.1200/JCO.22.02354
Volume 41(3) pgs. 423-711 January 20, 2023
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood, J M; Strawderman, M H; Ernstoff, M S; Smith, T J; Borden, E C; Blum, R H
doi : 10.1200/JCO.22.02264
Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma.
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy.
Corcoran, Ryan B. MD, PhD 1,,
doi : 10.1200/JCO.22.01922
Symptom Clusters in Childhood Cancer Survivors.
Bhatia, Smita MD, MPH 1,2,,; Landier, Wendy PhD 1,2,
doi : 10.1200/JCO.22.02051
Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.
Augustin, Ryan C. MD 1,2; Luke, Jason J. MD 1,2,,
doi : 10.1200/JCO.22.01770
Postmortem Tissue Donation: Giving Families the Ability to Choose.
Frenkel, Beth BSc 1; Gerasimov, Elena MA, MPH 2; Gustafson, Allen MA, DMin 3; Gustafson, Patti MA 3,; McLean, Ginny BA 3; Ochasi, Aloysius PhD 4; Waanders, Angela MD, MPH 5,6,; Ramaswamy, Vijay MD, PhD 7,8,
doi : 10.1200/JCO.21.02839
Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide.
Fenske, Timothy S. MD 1,,
doi : 10.1200/JCO.22.01661
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.
Parseghian, Christine M. MD 1; Sun, Ryan PhD 2,; Woods, Melanie BA 1; Napolitano, Stefania MD 3; Lee, Hey Min BS 1; Alshenaifi, Jumanah PhD 1; Willis, Jason MD, PhD 1,; Nunez, Shakayla BA 1; Raghav, Kanwal P. MD 1,; Morris, Van K. MD 1,; Shen, John P. MD, PhD 1,; Eluri, Madhulika MD 1; Sorokin, Alexey PhD 1; Kanikarla, Preeti PhD 1; Vilar, Eduardo MD, PhD 1,4,; Rehn, Marko PhD 5,; Ang, Agnes PhD 5,; Troiani, Teresa MD, PhD 3,; Kopetz, Scott MD, PhD 1,,
doi : 10.1200/JCO.22.01423
Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-pathway members.
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
Raghav, Kanwal MD 1,,; Ou, Fang-Shu PhD 2; Venook, Alan P. MD 3,; Innocenti, Federico MD, PhD 4,; Sun, Ryan PhD 1,; Lenz, Heinz-Josef MD 5,; Kopetz, Scott MD, PhD 1,
doi : 10.1200/JCO.22.00365
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine, Olivier MD, PhD 1,2,,; Jiang, Linmiao MSc 3; Walewski, Jan MD, PhD 4,; Bosly, Andre MD, PhD 5; Thieblemont, Catherine MD, PhD 6,; Szymczyk, Michal MD 4,; Pott, Christiane MD, PhD 7; Salles, Gilles MD, PhD 8,9,; Feugier, Pierre MD, PhD 10,; Hubel, Kai MD, PhD 11,; Haioun, Corinne MD, PhD 12,; Casasnovas, Rene Olivier MD 13,; Schmidt, Christian MD 14,; Bouabdallah, Kamal MD 15,; Ribrag, Vincent MD, PhD 16,; Kanz, Lothar MD, PhD 17,; Durig, Jan MD, PhD 18,; Metzner, Bernd MD, PhD 19; Sibon, David MD, PhD 1,; Cheminant, Morgane MD, PhD 1,; Burroni, Barbara MD 20; Klapper, Wolfram MD, PhD 21,; Hiddemann, Wolfgang MD, PhD 14; Unterhalt, Michael MD, PhD 14,; Hoster, Eva PhD 3,14; Dreyling, Martin MD, PhD 14,; on behalf of the European Mantle Cell Lymphoma Network
doi : 10.1200/JCO.22.01780
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
Topham, James T. MSc 1; O'Callaghan, Chris J. DVM, MSc, PhD 2; Feilotter, Harriet PhD 2,; Kennecke, Hagen F. MD 3,; Lee, Young S. PhD 4,; Li, Weimin PhD 4,; Banks, Kimberly C. MS, MBA 5,; Quinn, Katie PhD 5,; Renouf, Daniel J. MD 1,; Jonker, Derek J. MD 6; Tu, Dongsheng PhD 2; Chen, Eric X. MD, PhD 7,; Loree, Jonathan M. MD, MS 1,,
doi : 10.1200/JCO.22.00364
Anti-epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired resistance mechanisms may facilitate circulating tumor DNA (ctDNA) monitoring, anti-EGFR rechallenge, and combinatorial strategies to delay resistance.
Associations of Symptom Clusters and Health Outcomes in Adult Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study.
Shin, Hyewon PhD 1; Dudley, William N. PhD 2,; Bhakta, Nickhill MD, MPH 3,4; Horan, Madeline R. PhD 5; Wang, Zhaoming PhD 5; Bartlett, T. Robin PhD 6; Srivastava, Deokumar PhD 7,; Yasui, Yutaka PhD 5; Baker, Justin N. MD 4; Robison, Leslie L. PhD 5; Ness, Kirsten K. PT, PhD 5; Krull, Kevin R. PhD 5,8,; Hudson, Melissa M. MD 4,5,; Huang, I-Chan PhD 5,
doi : 10.1200/JCO.22.00361
To identify symptom clusters among adult survivors of childhood cancers and test associations with health-related quality of life (HRQOL) and physical and neurocognitive performance.
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Lerman, Benjamin J. MD, MS 1,; Li, Yimei PhD 1,2; Carlowicz, Cecilia BA 1; Granger, Meaghan MD 3; Cash, Thomas MSc, MD 4,; Sadanand, Arhanti MD 4; Somers, Katherine MD 5; Ranavaya, Aeesha MD 5; Weiss, Brian D. MD 5,; Choe, Michelle MD 6; Foster, Jennifer H. MD, MPH 6,; Pinto, Navin MD 7,; Morgenstern, Daniel A. PhD, MBBChir 8,; Rafael, Margarida Simao MD, MSc 8,9; Streby, Keri A. MD 10,; Zeno, Rachel N. MD 10; Mody, Rajen MD, MS 11,; Yazdani, Sahr MD 11; Desai, Ami V. MSCE, MD 12,; Macy, Margaret E. MD 13,; Shusterman, Suzanne MD 14,; Federico, Sara M. MD 15; Bagatell, Rochelle MD 1,
doi : 10.1200/JCO.22.01273
Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy.
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber, Jeffrey S. MD, PhD 1,,; Schadendorf, Dirk MD 2; Del Vecchio, Michele MD 3,; Larkin, James PhD, FRCP 4,; Atkinson, Victoria MD 5,; Schenker, Michael MD 6,; Pigozzo, Jacopo MD 7; Gogas, Helen MD, PhD 8,; Dalle, Stephane MD, PhD 9,; Meyer, Nicolas MD, PhD 10,; Ascierto, Paolo A. MD 11,; Sandhu, Shahneen MBBS 12,; Eigentler, Thomas MD 13,; Gutzmer, Ralf MD 14,; Hassel, Jessica C. MD 15,; Robert, Caroline MD, PhD 16,; Carlino, Matteo S. MBBS, PhD 17,; Di Giacomo, Anna Maria MD, PhD 18,; Butler, Marcus O. MD 19,; Munoz-Couselo, Eva MD 20,; Brown, Michael P. MBBS, PhD 21,; Rutkowski, Piotr MD 22,; Haydon, Andrew MD 23,; Grob, Jean-Jacques MD 24,; Schachter, Jacob MD, PhD 25,; Queirolo, Paola MD 26,27,; de la Cruz-Merino, Luis MD 28,; van der Westhuizen, Andre MBChB, MMed 29,; Menzies, Alexander M. MBBS, PhD 30,; Re, Sandra MD 31,; Bas, Tuba PhD 31,; de Pril, Veerle MSc 31,; Braverman, Julia PhD 31,; Tenney, Daniel J. PhD 31,; Tang, Hao PhD 31,; Long, Georgina V. MBBS, PhD 30,
doi : 10.1200/JCO.22.00533
Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney, Jason A. MD, PhD 1,,; Ribas, Antoni MD, PhD 2,; Long, Georgina V. MD, PhD 3,4,; Kirkwood, John M. MD 5,; Dummer, Reinhard MD 6,; Puzanov, Igor MD 7,; Hoeller, Christoph MD, PhD 8,; Gajewski, Thomas F. MD, PhD 9,; Gutzmer, Ralf MD 10,11,; Rutkowski, Piotr MD, PhD 12,; Demidov, Lev MD 13,; Arenberger, Petr MD, PhD 14,; Shin, Sang Joon MD 15; Ferrucci, Pier Francesco MD 16,; Haydon, Andrew MD 17,; Hyngstrom, John MD 18,; van Thienen, Johannes V. MD 19; Haferkamp, Sebastian MD, PhD 20,; Guilera, Josep Malvehy MD, PhD 21,; Rapoport, Bernardo Leon MD 22,23,; VanderWalde, Ari MD 24,; Diede, Scott J. MD 25,; Anderson, James R. PhD 25,; Treichel, Sheryl MS 26,; Chan, Edward L. MD 27,; Bhatta, Sumita MD 27,; Gansert, Jennifer MD 27,; Hodi, Frank Stephen MD 28; Gogas, Helen MD, PhD 29,
doi : 10.1200/JCO.22.00343
The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
Martin, Peter MD 1,,; Cohen, Jonathon B. MD, MS 2,; Wang, Michael MD 3,; Kumar, Anita MD 4,; Hill, Brian MD, PhD 5,; Villa, Diego MD 6,; Switchenko, Jeffrey M. PhD, MS 7; Kahl, Brad MD 8,; Maddocks, Kami MD 9,; Grover, Natalie S. MD 10,; Qi, Keqin PhD 11,; Parisi, Lori MPH 12,; Daly, Katherine PharmD, MS 12,; Zhu, Angeline PhD 12,; Salles, Gilles MD, PhD 4,
doi : 10.1200/JCO.21.02698
Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang, Michael MD 1,,; Munoz, Javier MD, MS, MBA 2,; Goy, Andre MD, MS 3,; Locke, Frederick L. MD 4,; Jacobson, Caron A. MD, MMSc 5,; Hill, Brian T. MD, PhD 6,; Timmerman, John M. MD 7,; Holmes, Houston MD, MBA 8,; Jaglowski, Samantha MD 9,; Flinn, Ian W. MD, PhD 10,; McSweeney, Peter A. MB, ChB 11,; Miklos, David B. MD, PhD 12,; Pagel, John M. MD, PhD, DSc 13,; Kersten, Marie Jose MD, PhD 14,; Bouabdallah, Krimo MD 15,; Khanal, Rashmi MD 16; Topp, Max S. MD 17,; Houot, Roch MD, PhD 18,; Beitinjaneh, Amer MD 19,; Peng, Weimin PhD 20,; Fang, Xiang PhD 20; Shen, Rhine R. PhD 20,; Siddiqi, Rubina PhD 20,; Kloos, Ioana MD 20,; Reagan, Patrick M. MD 21,
doi : 10.1200/JCO.21.02370
Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics.
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos, Meletios A. MD 1,,; Dytfeld, Dominik MD, PhD 2,; Grosicki, Sebastian MD, PhD 3; Moreau, Philippe MD 4,; Takezako, Naoki MD, PhD 5; Hori, Mitsuo MD, PhD 6; Leleu, Xavier MD, PhD 7,; LeBlanc, Richard MD 8,; Suzuki, Kenshi MD 9; Raab, Marc S. MD, PhD 10,; Richardson, Paul G. MD 11,; Popa McKiver, Mihaela MD, PhD 12,; Jou, Ying-Ming PhD 12,; Yao, David MD, PhD 12,; Das, Prianka PharmD 12,; San-Miguel, Jesus MD, PhD 13,
doi : 10.1200/JCO.21.02815
In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) previously treated with lenalidomide and a proteasome inhibitor (PI).
Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis.
Hui, David MD, MSc 1,,; Nortje, Nico PhD 2,3; George, Marina MD 4,; Wilson, Kaycee MEng 5; Urbauer, Diana L. MS 6; Lenz, Caitlin A. MSQM 5; Wallace, Susannah Kish PhD 7; Andersen, Clark R. MS 6; Mendoza, Tito PhD 8,; Haque, Sajid MD 3; Ahmed, Sairah MD 9,10,; Delgado-Guay, Marvin MD 1; Dalal, Shalini MD 1; Rathi, Nisha MD 2; Reddy, Akhila MD 1; McQuade, Jennifer MD 11,; Flowers, Christopher MD 9,12,; Pisters, Peter MD 13; Aloia, Thomas MD 14,; Bruera, Eduardo MD 1,
doi : 10.1200/JCO.22.00849
Many hospitals have established goals-of-care programs in response to the coronavirus disease 2019 pandemic; however, few have reported their outcomes. We examined the impact of a multicomponent interdisciplinary goals-of-care program on intensive care unit (ICU) mortality and hospital outcomes for medical inpatients with cancer.
A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
Hershman, Dawn L. MD, MS 1,,; Bansal, Aasthaa PhD 2,; Sullivan, Sean D. PhD 2,3,; Barlow, William E. PhD 2,4,; Arnold, Kathryn B. MS 2,4; Watabayashi, Kate BA 2,; Bell-Brown, Ari MPH 2; Le-Lindqwister, Nguyet A. MD 5; Dul, Carrie L. MD 6; Brown-Glaberman, Ursa A. MD 7,; Behrens, Robert J. MD 8; Vogel, Victor MD 9; Alluri, Nitya MD 10; Ramsey, Scott D. MD, PhD 2,
doi : 10.1200/JCO.22.01258
Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain.
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Konstantinopoulos, Panagiotis A. MD, PhD 1,,; Lee, Elizabeth K. MD 1,; Xiong, Niya MSc 1; Krasner, Carolyn MD 1,; Campos, Susana MD, MPH 1; Kolin, David L. MD, PhD 2,; Liu, Joyce F. MD, MPH 1,; Horowitz, Neil MD 2,; Wright, Alexi A. MD, MPH 1,; Bouberhan, Sara MD 3,; Penson, Richard T. MD 3,; Yeku, Oladapo MD, PhD 3,; Bowes, Brittany BSN 1; Needham, Hope BSc 1; Hayes, Martin BSc 1; Sawyer, Hannah BSc 1; Polak, Madeline BSc 1; Shea, Meghan MD 4,; Cheng, Su-Chun ScD 1; Castro, Cesar MD, MMSc 3,; Matulonis, Ursula A. MD 1,
doi : 10.1200/JCO.22.00628
Estrogen receptor (ER)-positive endometrial cancers (ECs) are characterized by phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/[beta]-catenin (CTNNB1) pathway alterations in approximately 90% and 80% of cases, respectively.
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro, Paul MD 1,,; Banerjee, Susana MD, PhD 2,; Colombo, Nicoletta MD, PhD 3,; Scambia, Giovanni MD 4,; Kim, Byoung-Gie MD, PhD 5; Oaknin, Ana MD, PhD 6,; Friedlander, Michael MD 7,; Lisyanskaya, Alla MD 8,; Floquet, Anne MD 9,10,; Leary, Alexandra MD 10,11,; Sonke, Gabe S. MD, PhD 12,; Gourley, Charlie MD, PhD 13,; Oza, Amit MD 14,; Gonzalez-Martin, Antonio MD, PhD 15,16,; Aghajanian, Carol MD 17,; Bradley, William MD 18,; Mathews, Cara MD 1,; Liu, Joyce MD 19,; McNamara, John MSc 20,; Lowe, Elizabeth S. MD 21,; Ah-See, Mei-Lin MB BChir, MD 22,; Moore, Kathleen N. MD 23,; on behalf of the SOLO1 Investigators
doi : 10.1200/JCO.22.01549
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 (BRCA) mutation.
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.
Brastianos, Priscilla K. MD 1,,; Twohy, Erin L. MS 2; Gerstner, Elizabeth R. MD 1,; Kaufmann, Timothy J. MD 3,; Iafrate, A. John MD, PhD 1,; Lennerz, Jochen MD 1; Jeyapalan, Suriya MD, MPH 4,; Piccioni, David E. MD, PhD 5; Monga, Varun MD 6,; Fadul, Camilo E. MD 7; Schiff, David MD 7,; Taylor, Jennie W. MD, MPH 8,; Chowdhary, Sajeel A. MD 9; Bettegowda, Chetan MD, PhD 10,; Ansstas, George MD 11,; De La Fuente, Macarena MD 12,; Anderson, Mark D. MD 13; Shonka, Nicole MD 14; Damek, Denise MD 15,; Carrillo, Jose MD 16; Kunschner-Ronan, Lara J. MD 17; Chaudhary, Rekha MD 18,; Jaeckle, Kurt A. MD 3,; Senecal, Francis M. MD 19; Kaley, Thomas MD 20; Morrison, Tara MD 21,; Thomas, Alissa A. MD 22,; Welch, Mary R. MD 23,; Iwamoto, Fabio MD 23,; Cachia, David MD 24,; Cohen, Adam L. MD 25,; Vora, Shivangi BE, MS 26; Knopp, Michael MD 26; Dunn, Ian F. MD 27; Kumthekar, Priya MD 28,; Sarkaria, Jann MD 3,; Geyer, Susan PhD 2,; Carrero, Xiomara W. BS 2; Martinez-Lage, Maria MD 1; Cahill, Daniel P. MD, PhD 1,; Brown, Paul D. MD 3,; Giannini, Caterina MD 3; Santagata, Sandro MD, PhD 29; Barker, Frederick G. II MD 1; Galanis, Evanthia MD 3,
doi : 10.1200/JCO.21.02371
Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with NF2 loss.
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
Sternberg, Cora N. MD 1,; Petrylak, Daniel P. MD 2,; Bellmunt, Joaquim MD 3,4,; Nishiyama, Hiroyuki MD 5,; Necchi, Andrea MD 6,; Gurney, Howard MBBS 7,; Lee, Jae-Lyun MD 8,; van der Heijden, Michiel S. MD 9,; Rosenbaum, Eli MD 10,; Penel, Nicolas MD 11,; Pang, See-Tong MD 12; Li, Jian-Ri MD 13; Garcia del Muro, Xavier MD 14,; Joly, Florence MD 15,; Papai, Zsuzsanna MD 16; Bao, Weichao PhD 17,; Ellinghaus, Peter PhD 18,; Lu, Chengxing PhD 17,; Sierecki, Mitchell MD 17,; Coppieters, Sabine MD 19,; Nakajima, Keiko MD 17,; Ishida, Tatiane Cristine MD 17,; Quinn, David I. MBBS, PhD 20,,
doi : 10.1200/JCO.21.02303
Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression.
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sadeghi, Sarmad MD, PhD 1,,; Quinn, David MD 1,; Dorff, Tanya MD 2,; Pal, Sumanta MD 2,; Groshen, Susan PhD 1; Tsao-Wei, Denice MS 1; Parikh, Rahul MD 3,; Devitt, Michael MD 4,; Parikh, Mamta MD 5,; Jackovich, Alexandra BA 6; Ruel, Nora MS 2,; Vogelzang, Nicholas MD 7,; Burgess, Earle MD 8,; Siddiqi, Imran MD 1,; Gill, Inderbir S. MD 1,; Lara, Primo N. MD 5,; Dreicer, Robert MD 4,; Gill, Parkash S. MD 1,
doi : 10.1200/JCO.21.02923
Patients with metastatic urothelial carcinoma have poor prognosis after failure of standard first-line chemotherapy. Immune check point programmed death 1-programmed death ligand 1 antibodies have low response rates and thus there exists a major unmet need.
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Wang, Zhijie MD 1,; Wu, Lin MD 2,; Li, Baolan MD 3; Cheng, Ying MD 4; Li, Xiaoling MD 5; Wang, Xicheng MD 6; Han, Liang MD 7; Wu, Xiaohong MD 8; Fan, Yun MD 9; Yu, Yan MD 10; Lv, Dongqing MD 11; Shi, Jianhua MD 12; Huang, Jianjin MD 13; Zhou, Shaozhang MD 14; Han, Baohui MD 15; Sun, Guogui MD 16; Guo, Qisen MD 17; Ji, Youxin MD 18; Zhu, Xiaoli MD 19; Hu, Sheng MD 20; Zhang, Wei MD 21; Wang, Qiming MD 22,; Jia, Yuming MD 23; Wang, Ziping MD 24; Song, Yong MD 25; Wu, Jingxun MD 26; Shi, Meiqi MD 27; Li, Xingya MD 28; Han, Zhigang MD 29; Liu, Yunpeng MD 30; Yu, Zhuang MD 31; Liu, An-Wen MD 32; Wang, Xiuwen MD 33; Zhou, Caicun MD 34; Zhong, Diansheng MD 35; Miao, Liyun MD 36; Zhang, Zhihong MD 37; Zhao, Hui MD 38; Yang, Jun MD 39; Wang, Dong MD 40; Wang, Yingyi MD 41; Li, Qiang MD 42; Zhang, Xiaodong MD 43; Ji, Mei MD 44; Yang, Zhenzhou MD 45; Cui, Jiuwei MD 46; Gao, Beili MD 47; Wang, Buhai MD 48; Liu, Hu MD 37; Nie, Lei MD 49; He, Mei MD 50; Jin, Shi MD 51; Gu, Wei MD 52; Shu, Yongqian MD 53; Zhou, Tong MD 54,; Feng, Jian MD 55; Yang, Xinmei MD 56; Huang, Cheng MD 57; Zhu, Bo MD 58; Yao, Yu MD 59; Tang, Xiongwen PhD, PhD 60,61,; Yu, Jianjun PhD, PhD 60,; Maher, Ellen MD 60,; Feng, Hui PhD 60,61,; Yao, Sheng PhD 60,61,; Keegan, Patricia MD 60,; Wang, Jie MD 1,
doi : 10.1200/JCO.22.00727
The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
Bouffet, Eric MD 1,,; Geoerger, Birgit MD, PhD 2,; Moertel, Christopher MD 3,; Whitlock, James A. MD 1,; Aerts, Isabelle MD 4,; Hargrave, Darren MD 5,; Osterloh, Lisa PhD 6,; Tan, Eugene PhD 7,; Choi, Jeea PhD 7,; Russo, Mark MD, PhD 7,; Fox, Elizabeth MD 8
doi : 10.1200/JCO.22.01000
BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600-mutant LGG; other cohorts will be reported elsewhere.
Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations.
Mason, Warren P. MD 1,,
doi : 10.1200/JCO.22.01914
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris, Van K. MD 1,; Kennedy, Erin B. MHSc 2; Baxter, Nancy N. MD, PhD 3; Benson, Al B. III MD 4,; Cercek, Andrea MD 5,; Cho, May MD 6,; Ciombor, Kristen K. MD, MSCI 7,; Cremolini, Chiara MD, PhD 8,; Davis, Anjee MPPA 9,; Deming, Dustin A. MD 10,; Fakih, Marwan G. MD 11,; Gholami, Sepideh MD 12,; Hong, Theodore S. MD 13,; Jaiyesimi, Ishmael DO 14; Klute, Kelsey MD 15,; Lieu, Christopher MD 16,; Sanoff, Hanna MD, MPH 17,; Strickler, John H. MD 18,; White, Sarah MD 19,; Willis, Jason A. MD, PhD 1,; Eng, Cathy MD 7,
doi : 10.1200/JCO.22.01690
To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Predicting the Risk of Progression in Patients With Kidney Cancer: Aiming at the Optimal Tool in the Optimal Setting.
Capitanio, Umberto MD; Rosiello, Giuseppe MD; Necchi, Andrea MD; Montorsi, Francesco MD; Larcher, Alessandro MD
doi : 10.1200/JCO.22.00680
Reply to U. Capitanio et al.
Oza, Bhavna MBBS; Eisen, Tim PhD; Stewart, Grant D. MBChB; Bex, Axel MD; Royston, Patrick DSc; Meade, Angela DPhil; On behalf of the authors on the SORCE TMG
doi : 10.1200/JCO.22.01124
Words Matter.
Benedetti, Daniel J. MD, MA; Marron, Jonathan M. MD, MPH; Thomas, Stefanie M. MD, MS; Caruso Brown, Amy E. MD, MSc, MSCS; Pyke-Grimm, Kimberly A. PhD; Johnson, Liza-Marie MD, MPH, MSB; Kodish, Eric MD; Unguru, Yoram MD, MS, MA
doi : 10.1200/JCO.22.01056
Reply to D.J. Benedetti et al.
DuBois, Steven G. MD; Gupta, Abha A. MD; Palmerini, Emanuela MD
doi : 10.1200/JCO.22.01401
Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More.
Kostopoulos, Ioannis V. MSc, PhD; Ntanasis-Stathopoulos, Ioannis MD, PhD; Rousakis, Pantelis MSc; Eleutherakis-Papaiakovou, Evangelos MD, PhD; Panteli, Chrysanthi MSc; Malandrakis, Panagiotis MD; Angelis, Nikolaos MSc; Kanellias, Nikolaos MD, PhD; Orologas-Stavrou, Nikolaos MSc, PhD; Papanota, Aristina MD; Fotiou, Despina MD, PhD; Migkou, Magdalini MD, PhD; Gavriatopoulou, Maria MD, PhD; Kastritis, Efstathios MD, PhD; Tsitsilonis, Ourania MD, PhD; Terpos, Evangelos MD, PhD; Dimopoulos, Meletios-Athanasios MD, PhD
doi : 10.1200/JCO.22.01606
Reply to I.V. Kostopoulos et al.
Garces, Juan-Jose PhD; San-Miguel, Jesus F. MD, PhD; Paiva, Bruno PhD
doi : 10.1200/JCO.22.01774
Flashback Foreword: Adjuvant Interferon [alpha]-2b for High-Risk Melanoma.
Schwartz, Gary K. MD 1,2,,
doi : 10.1200/JCO.22.02354
Volume 41(3) pgs. 423-711 January 20, 2023
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood, J M; Strawderman, M H; Ernstoff, M S; Smith, T J; Borden, E C; Blum, R H
doi : 10.1200/JCO.22.02264
Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma.
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy.
Corcoran, Ryan B. MD, PhD 1,,
doi : 10.1200/JCO.22.01922
Symptom Clusters in Childhood Cancer Survivors.
Bhatia, Smita MD, MPH 1,2,,; Landier, Wendy PhD 1,2,
doi : 10.1200/JCO.22.02051
Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.
Augustin, Ryan C. MD 1,2; Luke, Jason J. MD 1,2,,
doi : 10.1200/JCO.22.01770
Postmortem Tissue Donation: Giving Families the Ability to Choose.
Frenkel, Beth BSc 1; Gerasimov, Elena MA, MPH 2; Gustafson, Allen MA, DMin 3; Gustafson, Patti MA 3,; McLean, Ginny BA 3; Ochasi, Aloysius PhD 4; Waanders, Angela MD, MPH 5,6,; Ramaswamy, Vijay MD, PhD 7,8,
doi : 10.1200/JCO.21.02839
Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide.
Fenske, Timothy S. MD 1,,
doi : 10.1200/JCO.22.01661
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.
Parseghian, Christine M. MD 1; Sun, Ryan PhD 2,; Woods, Melanie BA 1; Napolitano, Stefania MD 3; Lee, Hey Min BS 1; Alshenaifi, Jumanah PhD 1; Willis, Jason MD, PhD 1,; Nunez, Shakayla BA 1; Raghav, Kanwal P. MD 1,; Morris, Van K. MD 1,; Shen, John P. MD, PhD 1,; Eluri, Madhulika MD 1; Sorokin, Alexey PhD 1; Kanikarla, Preeti PhD 1; Vilar, Eduardo MD, PhD 1,4,; Rehn, Marko PhD 5,; Ang, Agnes PhD 5,; Troiani, Teresa MD, PhD 3,; Kopetz, Scott MD, PhD 1,,
doi : 10.1200/JCO.22.01423
Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-pathway members.
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
Raghav, Kanwal MD 1,,; Ou, Fang-Shu PhD 2; Venook, Alan P. MD 3,; Innocenti, Federico MD, PhD 4,; Sun, Ryan PhD 1,; Lenz, Heinz-Josef MD 5,; Kopetz, Scott MD, PhD 1,
doi : 10.1200/JCO.22.00365
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine, Olivier MD, PhD 1,2,,; Jiang, Linmiao MSc 3; Walewski, Jan MD, PhD 4,; Bosly, Andre MD, PhD 5; Thieblemont, Catherine MD, PhD 6,; Szymczyk, Michal MD 4,; Pott, Christiane MD, PhD 7; Salles, Gilles MD, PhD 8,9,; Feugier, Pierre MD, PhD 10,; Hubel, Kai MD, PhD 11,; Haioun, Corinne MD, PhD 12,; Casasnovas, Rene Olivier MD 13,; Schmidt, Christian MD 14,; Bouabdallah, Kamal MD 15,; Ribrag, Vincent MD, PhD 16,; Kanz, Lothar MD, PhD 17,; Durig, Jan MD, PhD 18,; Metzner, Bernd MD, PhD 19; Sibon, David MD, PhD 1,; Cheminant, Morgane MD, PhD 1,; Burroni, Barbara MD 20; Klapper, Wolfram MD, PhD 21,; Hiddemann, Wolfgang MD, PhD 14; Unterhalt, Michael MD, PhD 14,; Hoster, Eva PhD 3,14; Dreyling, Martin MD, PhD 14,; on behalf of the European Mantle Cell Lymphoma Network
doi : 10.1200/JCO.22.01780
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
Topham, James T. MSc 1; O'Callaghan, Chris J. DVM, MSc, PhD 2; Feilotter, Harriet PhD 2,; Kennecke, Hagen F. MD 3,; Lee, Young S. PhD 4,; Li, Weimin PhD 4,; Banks, Kimberly C. MS, MBA 5,; Quinn, Katie PhD 5,; Renouf, Daniel J. MD 1,; Jonker, Derek J. MD 6; Tu, Dongsheng PhD 2; Chen, Eric X. MD, PhD 7,; Loree, Jonathan M. MD, MS 1,,
doi : 10.1200/JCO.22.00364
Anti-epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired resistance mechanisms may facilitate circulating tumor DNA (ctDNA) monitoring, anti-EGFR rechallenge, and combinatorial strategies to delay resistance.
Associations of Symptom Clusters and Health Outcomes in Adult Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study.
Shin, Hyewon PhD 1; Dudley, William N. PhD 2,; Bhakta, Nickhill MD, MPH 3,4; Horan, Madeline R. PhD 5; Wang, Zhaoming PhD 5; Bartlett, T. Robin PhD 6; Srivastava, Deokumar PhD 7,; Yasui, Yutaka PhD 5; Baker, Justin N. MD 4; Robison, Leslie L. PhD 5; Ness, Kirsten K. PT, PhD 5; Krull, Kevin R. PhD 5,8,; Hudson, Melissa M. MD 4,5,; Huang, I-Chan PhD 5,
doi : 10.1200/JCO.22.00361
To identify symptom clusters among adult survivors of childhood cancers and test associations with health-related quality of life (HRQOL) and physical and neurocognitive performance.
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Lerman, Benjamin J. MD, MS 1,; Li, Yimei PhD 1,2; Carlowicz, Cecilia BA 1; Granger, Meaghan MD 3; Cash, Thomas MSc, MD 4,; Sadanand, Arhanti MD 4; Somers, Katherine MD 5; Ranavaya, Aeesha MD 5; Weiss, Brian D. MD 5,; Choe, Michelle MD 6; Foster, Jennifer H. MD, MPH 6,; Pinto, Navin MD 7,; Morgenstern, Daniel A. PhD, MBBChir 8,; Rafael, Margarida Simao MD, MSc 8,9; Streby, Keri A. MD 10,; Zeno, Rachel N. MD 10; Mody, Rajen MD, MS 11,; Yazdani, Sahr MD 11; Desai, Ami V. MSCE, MD 12,; Macy, Margaret E. MD 13,; Shusterman, Suzanne MD 14,; Federico, Sara M. MD 15; Bagatell, Rochelle MD 1,
doi : 10.1200/JCO.22.01273
Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy.
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber, Jeffrey S. MD, PhD 1,,; Schadendorf, Dirk MD 2; Del Vecchio, Michele MD 3,; Larkin, James PhD, FRCP 4,; Atkinson, Victoria MD 5,; Schenker, Michael MD 6,; Pigozzo, Jacopo MD 7; Gogas, Helen MD, PhD 8,; Dalle, Stephane MD, PhD 9,; Meyer, Nicolas MD, PhD 10,; Ascierto, Paolo A. MD 11,; Sandhu, Shahneen MBBS 12,; Eigentler, Thomas MD 13,; Gutzmer, Ralf MD 14,; Hassel, Jessica C. MD 15,; Robert, Caroline MD, PhD 16,; Carlino, Matteo S. MBBS, PhD 17,; Di Giacomo, Anna Maria MD, PhD 18,; Butler, Marcus O. MD 19,; Munoz-Couselo, Eva MD 20,; Brown, Michael P. MBBS, PhD 21,; Rutkowski, Piotr MD 22,; Haydon, Andrew MD 23,; Grob, Jean-Jacques MD 24,; Schachter, Jacob MD, PhD 25,; Queirolo, Paola MD 26,27,; de la Cruz-Merino, Luis MD 28,; van der Westhuizen, Andre MBChB, MMed 29,; Menzies, Alexander M. MBBS, PhD 30,; Re, Sandra MD 31,; Bas, Tuba PhD 31,; de Pril, Veerle MSc 31,; Braverman, Julia PhD 31,; Tenney, Daniel J. PhD 31,; Tang, Hao PhD 31,; Long, Georgina V. MBBS, PhD 30,
doi : 10.1200/JCO.22.00533
Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney, Jason A. MD, PhD 1,,; Ribas, Antoni MD, PhD 2,; Long, Georgina V. MD, PhD 3,4,; Kirkwood, John M. MD 5,; Dummer, Reinhard MD 6,; Puzanov, Igor MD 7,; Hoeller, Christoph MD, PhD 8,; Gajewski, Thomas F. MD, PhD 9,; Gutzmer, Ralf MD 10,11,; Rutkowski, Piotr MD, PhD 12,; Demidov, Lev MD 13,; Arenberger, Petr MD, PhD 14,; Shin, Sang Joon MD 15; Ferrucci, Pier Francesco MD 16,; Haydon, Andrew MD 17,; Hyngstrom, John MD 18,; van Thienen, Johannes V. MD 19; Haferkamp, Sebastian MD, PhD 20,; Guilera, Josep Malvehy MD, PhD 21,; Rapoport, Bernardo Leon MD 22,23,; VanderWalde, Ari MD 24,; Diede, Scott J. MD 25,; Anderson, James R. PhD 25,; Treichel, Sheryl MS 26,; Chan, Edward L. MD 27,; Bhatta, Sumita MD 27,; Gansert, Jennifer MD 27,; Hodi, Frank Stephen MD 28; Gogas, Helen MD, PhD 29,
doi : 10.1200/JCO.22.00343
The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
Martin, Peter MD 1,,; Cohen, Jonathon B. MD, MS 2,; Wang, Michael MD 3,; Kumar, Anita MD 4,; Hill, Brian MD, PhD 5,; Villa, Diego MD 6,; Switchenko, Jeffrey M. PhD, MS 7; Kahl, Brad MD 8,; Maddocks, Kami MD 9,; Grover, Natalie S. MD 10,; Qi, Keqin PhD 11,; Parisi, Lori MPH 12,; Daly, Katherine PharmD, MS 12,; Zhu, Angeline PhD 12,; Salles, Gilles MD, PhD 4,
doi : 10.1200/JCO.21.02698
Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang, Michael MD 1,,; Munoz, Javier MD, MS, MBA 2,; Goy, Andre MD, MS 3,; Locke, Frederick L. MD 4,; Jacobson, Caron A. MD, MMSc 5,; Hill, Brian T. MD, PhD 6,; Timmerman, John M. MD 7,; Holmes, Houston MD, MBA 8,; Jaglowski, Samantha MD 9,; Flinn, Ian W. MD, PhD 10,; McSweeney, Peter A. MB, ChB 11,; Miklos, David B. MD, PhD 12,; Pagel, John M. MD, PhD, DSc 13,; Kersten, Marie Jose MD, PhD 14,; Bouabdallah, Krimo MD 15,; Khanal, Rashmi MD 16; Topp, Max S. MD 17,; Houot, Roch MD, PhD 18,; Beitinjaneh, Amer MD 19,; Peng, Weimin PhD 20,; Fang, Xiang PhD 20; Shen, Rhine R. PhD 20,; Siddiqi, Rubina PhD 20,; Kloos, Ioana MD 20,; Reagan, Patrick M. MD 21,
doi : 10.1200/JCO.21.02370
Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics.
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos, Meletios A. MD 1,,; Dytfeld, Dominik MD, PhD 2,; Grosicki, Sebastian MD, PhD 3; Moreau, Philippe MD 4,; Takezako, Naoki MD, PhD 5; Hori, Mitsuo MD, PhD 6; Leleu, Xavier MD, PhD 7,; LeBlanc, Richard MD 8,; Suzuki, Kenshi MD 9; Raab, Marc S. MD, PhD 10,; Richardson, Paul G. MD 11,; Popa McKiver, Mihaela MD, PhD 12,; Jou, Ying-Ming PhD 12,; Yao, David MD, PhD 12,; Das, Prianka PharmD 12,; San-Miguel, Jesus MD, PhD 13,
doi : 10.1200/JCO.21.02815
In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) previously treated with lenalidomide and a proteasome inhibitor (PI).
Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis.
Hui, David MD, MSc 1,,; Nortje, Nico PhD 2,3; George, Marina MD 4,; Wilson, Kaycee MEng 5; Urbauer, Diana L. MS 6; Lenz, Caitlin A. MSQM 5; Wallace, Susannah Kish PhD 7; Andersen, Clark R. MS 6; Mendoza, Tito PhD 8,; Haque, Sajid MD 3; Ahmed, Sairah MD 9,10,; Delgado-Guay, Marvin MD 1; Dalal, Shalini MD 1; Rathi, Nisha MD 2; Reddy, Akhila MD 1; McQuade, Jennifer MD 11,; Flowers, Christopher MD 9,12,; Pisters, Peter MD 13; Aloia, Thomas MD 14,; Bruera, Eduardo MD 1,
doi : 10.1200/JCO.22.00849
Many hospitals have established goals-of-care programs in response to the coronavirus disease 2019 pandemic; however, few have reported their outcomes. We examined the impact of a multicomponent interdisciplinary goals-of-care program on intensive care unit (ICU) mortality and hospital outcomes for medical inpatients with cancer.
A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
Hershman, Dawn L. MD, MS 1,,; Bansal, Aasthaa PhD 2,; Sullivan, Sean D. PhD 2,3,; Barlow, William E. PhD 2,4,; Arnold, Kathryn B. MS 2,4; Watabayashi, Kate BA 2,; Bell-Brown, Ari MPH 2; Le-Lindqwister, Nguyet A. MD 5; Dul, Carrie L. MD 6; Brown-Glaberman, Ursa A. MD 7,; Behrens, Robert J. MD 8; Vogel, Victor MD 9; Alluri, Nitya MD 10; Ramsey, Scott D. MD, PhD 2,
doi : 10.1200/JCO.22.01258
Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain.
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Konstantinopoulos, Panagiotis A. MD, PhD 1,,; Lee, Elizabeth K. MD 1,; Xiong, Niya MSc 1; Krasner, Carolyn MD 1,; Campos, Susana MD, MPH 1; Kolin, David L. MD, PhD 2,; Liu, Joyce F. MD, MPH 1,; Horowitz, Neil MD 2,; Wright, Alexi A. MD, MPH 1,; Bouberhan, Sara MD 3,; Penson, Richard T. MD 3,; Yeku, Oladapo MD, PhD 3,; Bowes, Brittany BSN 1; Needham, Hope BSc 1; Hayes, Martin BSc 1; Sawyer, Hannah BSc 1; Polak, Madeline BSc 1; Shea, Meghan MD 4,; Cheng, Su-Chun ScD 1; Castro, Cesar MD, MMSc 3,; Matulonis, Ursula A. MD 1,
doi : 10.1200/JCO.22.00628
Estrogen receptor (ER)-positive endometrial cancers (ECs) are characterized by phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/[beta]-catenin (CTNNB1) pathway alterations in approximately 90% and 80% of cases, respectively.
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro, Paul MD 1,,; Banerjee, Susana MD, PhD 2,; Colombo, Nicoletta MD, PhD 3,; Scambia, Giovanni MD 4,; Kim, Byoung-Gie MD, PhD 5; Oaknin, Ana MD, PhD 6,; Friedlander, Michael MD 7,; Lisyanskaya, Alla MD 8,; Floquet, Anne MD 9,10,; Leary, Alexandra MD 10,11,; Sonke, Gabe S. MD, PhD 12,; Gourley, Charlie MD, PhD 13,; Oza, Amit MD 14,; Gonzalez-Martin, Antonio MD, PhD 15,16,; Aghajanian, Carol MD 17,; Bradley, William MD 18,; Mathews, Cara MD 1,; Liu, Joyce MD 19,; McNamara, John MSc 20,; Lowe, Elizabeth S. MD 21,; Ah-See, Mei-Lin MB BChir, MD 22,; Moore, Kathleen N. MD 23,; on behalf of the SOLO1 Investigators
doi : 10.1200/JCO.22.01549
In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 (BRCA) mutation.
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.
Brastianos, Priscilla K. MD 1,,; Twohy, Erin L. MS 2; Gerstner, Elizabeth R. MD 1,; Kaufmann, Timothy J. MD 3,; Iafrate, A. John MD, PhD 1,; Lennerz, Jochen MD 1; Jeyapalan, Suriya MD, MPH 4,; Piccioni, David E. MD, PhD 5; Monga, Varun MD 6,; Fadul, Camilo E. MD 7; Schiff, David MD 7,; Taylor, Jennie W. MD, MPH 8,; Chowdhary, Sajeel A. MD 9; Bettegowda, Chetan MD, PhD 10,; Ansstas, George MD 11,; De La Fuente, Macarena MD 12,; Anderson, Mark D. MD 13; Shonka, Nicole MD 14; Damek, Denise MD 15,; Carrillo, Jose MD 16; Kunschner-Ronan, Lara J. MD 17; Chaudhary, Rekha MD 18,; Jaeckle, Kurt A. MD 3,; Senecal, Francis M. MD 19; Kaley, Thomas MD 20; Morrison, Tara MD 21,; Thomas, Alissa A. MD 22,; Welch, Mary R. MD 23,; Iwamoto, Fabio MD 23,; Cachia, David MD 24,; Cohen, Adam L. MD 25,; Vora, Shivangi BE, MS 26; Knopp, Michael MD 26; Dunn, Ian F. MD 27; Kumthekar, Priya MD 28,; Sarkaria, Jann MD 3,; Geyer, Susan PhD 2,; Carrero, Xiomara W. BS 2; Martinez-Lage, Maria MD 1; Cahill, Daniel P. MD, PhD 1,; Brown, Paul D. MD 3,; Giannini, Caterina MD 3; Santagata, Sandro MD, PhD 29; Barker, Frederick G. II MD 1; Galanis, Evanthia MD 3,
doi : 10.1200/JCO.21.02371
Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with NF2 loss.
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
Sternberg, Cora N. MD 1,; Petrylak, Daniel P. MD 2,; Bellmunt, Joaquim MD 3,4,; Nishiyama, Hiroyuki MD 5,; Necchi, Andrea MD 6,; Gurney, Howard MBBS 7,; Lee, Jae-Lyun MD 8,; van der Heijden, Michiel S. MD 9,; Rosenbaum, Eli MD 10,; Penel, Nicolas MD 11,; Pang, See-Tong MD 12; Li, Jian-Ri MD 13; Garcia del Muro, Xavier MD 14,; Joly, Florence MD 15,; Papai, Zsuzsanna MD 16; Bao, Weichao PhD 17,; Ellinghaus, Peter PhD 18,; Lu, Chengxing PhD 17,; Sierecki, Mitchell MD 17,; Coppieters, Sabine MD 19,; Nakajima, Keiko MD 17,; Ishida, Tatiane Cristine MD 17,; Quinn, David I. MBBS, PhD 20,,
doi : 10.1200/JCO.21.02303
Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression.
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sadeghi, Sarmad MD, PhD 1,,; Quinn, David MD 1,; Dorff, Tanya MD 2,; Pal, Sumanta MD 2,; Groshen, Susan PhD 1; Tsao-Wei, Denice MS 1; Parikh, Rahul MD 3,; Devitt, Michael MD 4,; Parikh, Mamta MD 5,; Jackovich, Alexandra BA 6; Ruel, Nora MS 2,; Vogelzang, Nicholas MD 7,; Burgess, Earle MD 8,; Siddiqi, Imran MD 1,; Gill, Inderbir S. MD 1,; Lara, Primo N. MD 5,; Dreicer, Robert MD 4,; Gill, Parkash S. MD 1,
doi : 10.1200/JCO.21.02923
Patients with metastatic urothelial carcinoma have poor prognosis after failure of standard first-line chemotherapy. Immune check point programmed death 1-programmed death ligand 1 antibodies have low response rates and thus there exists a major unmet need.
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Wang, Zhijie MD 1,; Wu, Lin MD 2,; Li, Baolan MD 3; Cheng, Ying MD 4; Li, Xiaoling MD 5; Wang, Xicheng MD 6; Han, Liang MD 7; Wu, Xiaohong MD 8; Fan, Yun MD 9; Yu, Yan MD 10; Lv, Dongqing MD 11; Shi, Jianhua MD 12; Huang, Jianjin MD 13; Zhou, Shaozhang MD 14; Han, Baohui MD 15; Sun, Guogui MD 16; Guo, Qisen MD 17; Ji, Youxin MD 18; Zhu, Xiaoli MD 19; Hu, Sheng MD 20; Zhang, Wei MD 21; Wang, Qiming MD 22,; Jia, Yuming MD 23; Wang, Ziping MD 24; Song, Yong MD 25; Wu, Jingxun MD 26; Shi, Meiqi MD 27; Li, Xingya MD 28; Han, Zhigang MD 29; Liu, Yunpeng MD 30; Yu, Zhuang MD 31; Liu, An-Wen MD 32; Wang, Xiuwen MD 33; Zhou, Caicun MD 34; Zhong, Diansheng MD 35; Miao, Liyun MD 36; Zhang, Zhihong MD 37; Zhao, Hui MD 38; Yang, Jun MD 39; Wang, Dong MD 40; Wang, Yingyi MD 41; Li, Qiang MD 42; Zhang, Xiaodong MD 43; Ji, Mei MD 44; Yang, Zhenzhou MD 45; Cui, Jiuwei MD 46; Gao, Beili MD 47; Wang, Buhai MD 48; Liu, Hu MD 37; Nie, Lei MD 49; He, Mei MD 50; Jin, Shi MD 51; Gu, Wei MD 52; Shu, Yongqian MD 53; Zhou, Tong MD 54,; Feng, Jian MD 55; Yang, Xinmei MD 56; Huang, Cheng MD 57; Zhu, Bo MD 58; Yao, Yu MD 59; Tang, Xiongwen PhD, PhD 60,61,; Yu, Jianjun PhD, PhD 60,; Maher, Ellen MD 60,; Feng, Hui PhD 60,61,; Yao, Sheng PhD 60,61,; Keegan, Patricia MD 60,; Wang, Jie MD 1,
doi : 10.1200/JCO.22.00727
The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
Bouffet, Eric MD 1,,; Geoerger, Birgit MD, PhD 2,; Moertel, Christopher MD 3,; Whitlock, James A. MD 1,; Aerts, Isabelle MD 4,; Hargrave, Darren MD 5,; Osterloh, Lisa PhD 6,; Tan, Eugene PhD 7,; Choi, Jeea PhD 7,; Russo, Mark MD, PhD 7,; Fox, Elizabeth MD 8
doi : 10.1200/JCO.22.01000
BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600-mutant LGG; other cohorts will be reported elsewhere.
Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations.
Mason, Warren P. MD 1,,
doi : 10.1200/JCO.22.01914
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris, Van K. MD 1,; Kennedy, Erin B. MHSc 2; Baxter, Nancy N. MD, PhD 3; Benson, Al B. III MD 4,; Cercek, Andrea MD 5,; Cho, May MD 6,; Ciombor, Kristen K. MD, MSCI 7,; Cremolini, Chiara MD, PhD 8,; Davis, Anjee MPPA 9,; Deming, Dustin A. MD 10,; Fakih, Marwan G. MD 11,; Gholami, Sepideh MD 12,; Hong, Theodore S. MD 13,; Jaiyesimi, Ishmael DO 14; Klute, Kelsey MD 15,; Lieu, Christopher MD 16,; Sanoff, Hanna MD, MPH 17,; Strickler, John H. MD 18,; White, Sarah MD 19,; Willis, Jason A. MD, PhD 1,; Eng, Cathy MD 7,
doi : 10.1200/JCO.22.01690
To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Predicting the Risk of Progression in Patients With Kidney Cancer: Aiming at the Optimal Tool in the Optimal Setting.
Capitanio, Umberto MD; Rosiello, Giuseppe MD; Necchi, Andrea MD; Montorsi, Francesco MD; Larcher, Alessandro MD
doi : 10.1200/JCO.22.00680
Reply to U. Capitanio et al.
Oza, Bhavna MBBS; Eisen, Tim PhD; Stewart, Grant D. MBChB; Bex, Axel MD; Royston, Patrick DSc; Meade, Angela DPhil; On behalf of the authors on the SORCE TMG
doi : 10.1200/JCO.22.01124
Words Matter.
Benedetti, Daniel J. MD, MA; Marron, Jonathan M. MD, MPH; Thomas, Stefanie M. MD, MS; Caruso Brown, Amy E. MD, MSc, MSCS; Pyke-Grimm, Kimberly A. PhD; Johnson, Liza-Marie MD, MPH, MSB; Kodish, Eric MD; Unguru, Yoram MD, MS, MA
doi : 10.1200/JCO.22.01056
Reply to D.J. Benedetti et al.
DuBois, Steven G. MD; Gupta, Abha A. MD; Palmerini, Emanuela MD
doi : 10.1200/JCO.22.01401
Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More.
Kostopoulos, Ioannis V. MSc, PhD; Ntanasis-Stathopoulos, Ioannis MD, PhD; Rousakis, Pantelis MSc; Eleutherakis-Papaiakovou, Evangelos MD, PhD; Panteli, Chrysanthi MSc; Malandrakis, Panagiotis MD; Angelis, Nikolaos MSc; Kanellias, Nikolaos MD, PhD; Orologas-Stavrou, Nikolaos MSc, PhD; Papanota, Aristina MD; Fotiou, Despina MD, PhD; Migkou, Magdalini MD, PhD; Gavriatopoulou, Maria MD, PhD; Kastritis, Efstathios MD, PhD; Tsitsilonis, Ourania MD, PhD; Terpos, Evangelos MD, PhD; Dimopoulos, Meletios-Athanasios MD, PhD
doi : 10.1200/JCO.22.01606
Reply to I.V. Kostopoulos et al.
Garces, Juan-Jose PhD; San-Miguel, Jesus F. MD, PhD; Paiva, Bruno PhD
doi : 10.1200/JCO.22.01774
